HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

News Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:09:12 05/06/2026 BST			5-day change	1st Jan Change
29.32 ^HKD	-1.61%		-6.74%	-18.74%

06-04	Hansoh Pharmaceutical's Weight-loss Injection Enters China Review	MT
05-28	Higher Crude, Persian Gulf Outlooks Lowers Asian Stock Markets	MT

All News

Mentions Relevance

06-04	Hansoh Pharmaceutical's Weight-loss Injection Enters China Review	MT
05-22	Hansoh Pharma Clinches NMPA Breakthrough Designation for Fourth-Gen Cancer Tablet	MT
05-15	Hansoh Pharmaceutical Group Company Limited Announces Changes of Joint Company Secretary with Effect from May 15, 2026	CI
05-15	Hansoh Pharmaceutical : SID 2026 \| HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS	PU
05-14	Hansoh Pharma Gets China Nod for Trial of Tumor Drug	MT
05-13	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval for Hs-10541 Tablets	CI
05-13	Hansoh pharmaceutical says HS-10541 tablets obtain clinical trial approval from China's NMPA	RE
05-11	The Nmpa Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093For Esophageal Squamous Cell Carcinoma	CI
05-11	Hansoh Pharmaceutical's HS-20093 Receives China Breakthrough Therapy Designation in Another Indication	MT
05-11	Hansoh pharmaceutical says NMPA grants breakthrough-therapy designation to Hansoh Pharma's HS-20093 for ESCC	RE
04-29	Hansoh pharmaceutical transfers kiomedinevsone license to Jiangsu Hengrui Pharmaceuticals	RE
04-29	Hansoh Pharmaceutical Group Company Limited Announces Nmpa Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for Castration-Resistant Prostate Cancer	CI
04-29	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approvals for HS-10522 Tablets	CI
04-28	Hansoh Pharmaceutical : ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025	PU
04-22	Hansoh Pharmaceutical : AACR 2026 \| HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC	PU
04-20	Hansoh Pharmaceutical : AACR 2026 \| HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS	PU
04-17	Hansoh Pharmaceutical : AAN 2026 \| HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA	PU
04-16	Hansoh Pharmaceutical's Lung Cancer Drug Gets Breakthrough Therapy Designation in China	MT
04-16	Hansoh Pharmaceutical says NMPA grants breakthrough-therapy designation to HS-20093 with adebrelimab	RE
04-16	Hansoh Pharmaceutical Group Company Limited Announces NMPA Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 in Combination with Adebrelimab	CI
04-03	Hansoh Pharmaceutical : PHARMA – XINYUE’S THIRD INDICATION APPROVED FOR MARKETING FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS	PU
04-02	Jiangsu Hansoh Pharmaceutical Co., Ltd. Announces Third Indication Approval For XINYUE For Treatment Of Generalized Myasthenia Gravis In Adult Patients	CI
03-31	Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$38 From HK$37.87, Keeps at Neutral	MT
03-30	Hansoh Pharmaceutical's Profit, Revenue Climb in 2025	MT
03-29	Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI